Bayer to present new cardiorenal data for Kerendia™ (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes
Home /Health/Bayer to present new cardiorenal data for Kerendia™ (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes